All News

This might be the greatest honor of my career - thanks for including me @ACRheum!! Serious question and I’m not sure I want to know the answer Did anyone know the answer? Would be embarrassing 😂🤣😅😳 #ACR22 #KnowledgeBowl #RheumPix @RheumNow https://t.co/GhjXUgCgye

Daikeler et al. No change in incidence permanent vision loss in GCA at 17%. Late presentation (after PVL) and missed diagnosis key areas for improvement. @rheumnow #ACR22 Abstr#0476 https://t.co/CYBHm8CCBv https://t.co/jIvouncdxw

Permanent Vision Loss in Giant Cell Arteritis: Why the Incidence Remains High -…

Don't repeat the ENA test! Retrospect. study 23,438 ENA testing from 19,603 pts: 10% + (mostly Ro52 Ab), 89% neg. 13.4% had ENA test repeated. 96% stable results w/o change Conclusion: ENA results rarely change or yield new diagnosis of AARD #ACR22 @rheumnow abst#0725

What's the best tx strategy for SLE-induced severe thrombocytopenia? This 10-yr retro study by Dr. Cime-Ake et al. showed that RTX provided longer relapse-free survival (vs. CYC, p=0.040). No difference between IV or oral GCs and AZA or MMF. #ACR22 @RheumNow ABST#368 https://t.co/nzXZMY09jx

Interim RELIANCE registry data of FMF patients treated with Canakinumab shows efficacy and safety of long-term tx including w/ dose adjustments. Abs 0138 #ACR22 @RheumNow https://t.co/ornfXVIw49 https://t.co/eHTIIEhE37

Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment - …

Khursheed @LatikaGupta_ et al. Gender gap in rheumatology leadership. Improvements over time in ACR and some APLAR countries, but remains hugely imbalanced @rheumnow #ACR22 Abstr#0085 https://t.co/gw4HYaRlIY https://t.co/xueC3cfqyu

Closing the Gender Gap in Global Rheumatology Leadership- Are We There Yet? - A…

Should you repeat the dsDNA? SMART-SLE study >3400 SLE pts, > 37,582 visits. Pts with fluctuating + results or persistently + had higher rates of SLE flares HR 1.56 (95% CI 1.3-1.87, p< 0.001). Inc or Dec dsDNA Ab > 2X from last visit can predict flares @rheumnow #ACR22 abst#0327

❤️ Beta Blockers in LV-GCA 📚65 pts LV-GCA 💊 15(23%) on BB, 50(73%) not 🩻 new aortic dilatation on serial imaging in 15 (23%) - ALL in those NOT on beta blocker 💔 More studies needed, but supportive initial data 🔥 @RheumNow #ACR22 Abst#0477

#abs0127 #acr22 @rheumnow 59 adults pts from SAPHO-CNO Study (SCS) reported high scores (0.8 or >SD) for pain interference& fatigue domains vs general population. ⬇️ score on PROMIS physical function; 72.9% of subjects had a T-score < 45. https://t.co/5QfwlB98wV

#ACR22 Abstr#0769 In patients on DMARDs who didnt seroconvert after primary mRNA COVID vac, is switching to vector or booster with mRNA more effective? An RCT (N=46) showed more pts receiving booster mRNA seroconverted (63%) vs vector (18%). Tcell response was similar @RheumNow https://t.co/5GTsdhNUQZ

Barajas-Ochoa et al. Gender representation in editorial boards of rheum journals. Only 28% women editors overall. Clear discrepancies between journals. Well done @ACR_Journals ! @rheumnow #ACR22 Abstr#104 https://t.co/dpElAUSEuS https://t.co/rDAG6HwNf4

Gender Representation of the Editors and Editorial Boards of the Top 45 Rheumat…

Neural networks help distinguish between inflammatory arthritis, RA vs PsA, based on MRI inflammatory patterns, focusing on regions of clinical relevance. Fascinating use of tech that needs to be further evaluated clinically. Abs 0242 #ACR22 @RheumNow https://t.co/EMJZkFaMwu https://t.co/hNf70PaZX6

Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthriti…

❓Vessel wall MRI superior to TA-US in c-GCA❓ 🔥In c-GCA vessel wall MRI examines beyond the temporal arteries - ✅more 🧠 cranial arteries, including occipital arteries and the all important 👁 orbital structures Abst#0473 #ACR22 @RheumNow @RennieRhee https://t.co/ayuPP5v7Lh

Tune in to Twitter, Facebook or LinkedIn daily at 5pm ET! #ACR22 https://t.co/BPlVx0rRCd

Prieto-Pena et al. Tocilizumab in GCA and TAK. Observational study of 70 GCA, 57 TAK in Spain. Similar efficacy in both diseases. @rheumnow #ACR22 Abstr#0465 https://t.co/pyKAILryhH https://t.co/Csp7FIgnzD

Tocilizumab in Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: Multic…

After bDMARD treatment for 1 year in AxSpA, the gut microbiota composition: ◦ more resembled controls ◦ Enrichment of Collinsella remained stable ◦ Depletion of some species in HLA-B27+ patients from baseline https://t.co/Mw4MToqFcQ Poddubnyy et al @ProftDr #ACR22 @RheumNow

Improvement of Gut Microbiota Dysbiosis in Patients with Axial Spondyloarthriti…

#ACR22 Abs 0256 identified different autoantibodies in ACPA+ and ACPA– RA. Study shows potential utility of serum autoantibodies as diagnostic targets for RA subgroups & treatments. This study reminds me of @RheumNow teaching that not all RA created equal. https://t.co/Fjjk6uC0pB https://t.co/Ozr32cJojr

Patients with ACPA-positive and ACPA-negative Rheumatoid Arthritis Show Differe…

“It's not that I'm so smart, it's just that I stay with problems longer.” Einstein Love the quote in the community hub for early career @NIAMSFunding - Perseverance is the KEY in this funding world #ACR22 @RheumNow

Figueroa-Parra et al @AliDuarteMD Preventative services in SLE better in some areas and worse in some than comparators. Overall cervical screening, osteoporosis, dyslipidaemia low in this high risk group @rheumnow #ACR22 Abstr#0064 https://t.co/fHQ7ct6yt5 https://t.co/x7gHUDA8zo

Utilization of Preventive Services in a Systemic Lupus Erythematosus Population…

Wilding et al. Mortality in AAV 1/5/10-year survival 90%/73%/57% in AAV, 97%/86%/73% controls (p <0.0001). Highest 1st year - often vasculitis related (35%). After this - infection (28% vs 19%) @rheumnow #ACR22 Abstr#0448 https://t.co/YwwaaB6jDS https://t.co/ogrJkLAd1v

All-Cause and Cause-Specific Mortality in ANCA-Associated Vasculitis: A Populat…

Topics

All News

Do you get our email newsletter?